Drug Trial Radar · NCT06387342
Namodenoson Treatment of Advanced Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Nov 10, 2024
Primary completion
Jul 15, 2026
Study completion Dec 15, 2026
Sponsor
- Lead sponsor
- Can-Fite BioPharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.
Conditions
- Pancreatic Adenocarcinoma
- Pancreatic Cancer
Interventions
Namodenoson 25mgDrug
oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: Every 2 weeks, assessed up to 1 year
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baselineTime frame: Every 2 weeks, assessed up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rabin Medical Center Institute of Oncology
Petah Tikva, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.